It is an exciting time in the field of graft versus host disease (GvHD) research, as new drugs for the treatment of this disease in post-transplant patients have been FDA approved or received breakthrough therapy designation. Such drugs include ruxolitinib and ibrutinib, and although these drugs have shown to be effective in treating patients with GvHD, there are still challenges that pharmacists must be aware of. Here, Katie Gatwood, PharmD, BCOP, of Vanderbilt University Medical Center, Nashville, TN, explains the challenges that come with this therapy and the importance of pharmacist intervention when using ruxolitinib or ibrutinib for the treatment of GvHD. This interview was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.
The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib
